GT Biopharma (NASDAQ: GTBP), focused on the development and commercialization of its disruptive, target-directed Natural Killer (“NK”) cell engager immunotherapy protein biologic platform technology: TriKE(TM) for cancer and infectious diseases, has closed an underwritten public offering of 4,945,000 units. According to the update, the offering includes an additional 645,000 units pursuant to the full exercise of the over-allotment option granted to the underwriters. GT Biopharma secured approximately $27.2 million in gross proceeds, with each unit consisting of one share of GT Biopharma’s common stock and one warrant to purchase one share of common stock sold at a public offering price of $5.50. ROTH Capital Partners acted as joint book-running manager for the offering.
To view the full press release, visit https://nnw.fm/Qq6uv
About GT Biopharma Inc.
GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on its proprietary Trispecific Killer Engagers (“TriKE(TM)”) target-directed Natural Killer (“NK”) cell engager platform. The TriKE NK protein biologic platform is designed to harness and amplify the body’s native immune system for hope for patients with cancer and infectious diseases. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota, where Jeffery S. Miller, M.D., GT Biopharma’s consulting chief medical officer, developed the TriKE to further develop and commercialize therapies using TriKE technology. For more information, please visit www.GTBiopharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork
